These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38916821)

  • 1. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience.
    Singareeka Raghavendra A; Liu D; Shen Y; Barcenas CH; Ueno NT; Giordano S; Tripathy D; Sri Karuturi M
    Breast Cancer Res Treat; 2024 Aug; 207(1):81-90. PubMed ID: 38916821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
    Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
    Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
    Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
    Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
    Sharma P; López-Tarruella S; García-Saenz JA; Khan QJ; Gómez HL; Prat A; Moreno F; Jerez-Gilarranz Y; Barnadas A; Picornell AC; Monte-Millán MD; González-Rivera M; Massarrah T; Pelaez-Lorenzo B; Palomero MI; González Del Val R; Cortés J; Fuentes-Rivera H; Morales DB; Márquez-Rodas I; Perou CM; Lehn C; Wang YY; Klemp JR; Mammen JV; Wagner JL; Amin AL; O'Dea AP; Heldstab J; Jensen RA; Kimler BF; Godwin AK; Martín M
    Clin Cancer Res; 2018 Dec; 24(23):5820-5829. PubMed ID: 30061361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
    Kern P; Kalisch A; von Minckwitz G; Pütter C; Kolberg HC; Pott D; Kurbacher C; Rezai M; Kimmig R
    J Chemother; 2016 Jun; 28(3):210-7. PubMed ID: 26239282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-based chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
    Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
    Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
    Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
    Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
    Tzikas AK; Nemes S; Linderholm BK
    Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
    Schreiber AR; Kagihara J; Eguchi M; Kabos P; Fisher CM; Meyer E; Molina E; Kondapalli L; Bradley CJ; Diamond JR
    Breast Cancer Res Treat; 2022 Jan; 191(2):389-399. PubMed ID: 34705147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
    Martín M; Yoder R; Salgado R; Del Monte-Millán M; Álvarez EL; Echavarría I; Staley JM; O'Dea AP; Nye LE; Stecklein SR; Bueno C; Jerez Y; Cebollero M; Bueno O; García Saenz JÁ; Moreno F; Bohn U; Gómez H; Massarrah T; Khan QJ; Godwin AK; López-Tarruella S; Sharma P
    Clin Cancer Res; 2024 May; 30(10):2160-2169. PubMed ID: 38466643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
    Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
    Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
    Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
    Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
    World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.